5-(2-methylpentan-2-yl)benzene-1,3-diol | 180415-84-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(2-methylpentan-2-yl)benzene-1,3-diol
• 英文别名: 5-(1,1-dimethyl-butyl)-resorcinol；3.5-Dihydroxy-1-(1.1-dimethyl-butyl)-benzol；5-(1,1-Dimethyl-butyl)-resorcin；2-methyl-2-(3,5-dihydroxyphenyl)pentane；5-(1,1-Dimethylbutyl)resorcinol
• CAS: 180415-84-3
• 化学式: C₁₂H₁₈O₂
• 分子量: 194.274
• InChiKey: QEPQVDCYJKTYAU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(2-methylpentan-2-yl)benzene-1,3-diol 在 氨 、 lithium 、 sodium hydride 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 乙醚 、 苯 为溶剂， 生成 (6AR,10AR)-3-(1,1-二甲基丁基)-6A,7,10,10A-四氢-6,6,9-三甲基-6H-二苯并[B,D]吡喃
  参考文献：
  名称：

  3-（1'，1'-二甲基丁基）-1-脱氧-δ8-THC和相关化合物：CB2受体选择性配体的合成。

  摘要：

  描述了15个1-deoxy-delta8-THC类似物的合成和药理作用，其中一些对CB2受体具有高亲和力。所述脱氧大麻素包括1-脱氧-11-羟基-δ8-THC（5），1-脱氧δ8-THC（6），1-脱氧-3-丁基-δ8-THC（7），1-脱氧-3 -hexyl-delta8-THC（8）和一系列3-（1'，1'-二甲基烷基）-1-deoxy-delta8-THC类似物（2，n = 0-4，6，7，其中n =侧链中的碳原子数-2）。还制备了脱氧萘丁酮（16）的三种衍生物（17-19）。使用前述方法确定每种化合物对CB1和CB2受体的亲和力。3-（1'，1'-二甲基烷基）-1-脱氧-delta8-THC类似物中的五个（2，n = 1-5）对CB2受体具有高亲和力（Ki = <20 nM）。其中四个（2，n = 1-4）对CB1受体的亲和力也很小（Ki => 295 nM）。3-（1'，1'-二

  DOI：

  10.1016/s0968-0896(99)00219-9
• 作为产物：
  描述：

  2-甲基-2-戊醇 在 甲烷磺酸 、 氨 、 三溴化硼 、 lithium 、 三乙胺 作用下， 以 四氢呋喃 、 四氯化碳 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 5-(2-methylpentan-2-yl)benzene-1,3-diol
  参考文献：
  名称：

  Structure–activity relationships for 1′,1′-dimethylalkyl-Δ 8 -tetrahydrocannabinols

  摘要：

  A series of 1',1'-dimethylalkyl-Delta(8)-tetrahydrocannabinol analogues with C-3 side chains of 2-12 carbon atoms has been synthesized and their in vitro and in vivo pharmacology has been evaluated. The lowest member of the series, 1',1'-dimethylethyl-Delta(8)-THC (8, n = 0) has good affinity for the CB1 receptor, but is inactive in vivo. The dimethylpropyl (8, n = 1) through dimethyldecyl (8, n = 8) all have high affinity for the CB1 receptor and are full agonists in vivo. 1',1'-Dimethylundecyl-Delta(8)-THC (8, n = 9) has significant affinity for the receptor (K-i = 25.8 +/- 5.8 nM), but has reduced potency in vivo. The dodecyl analogue (8, n = 10) has little affinity for the CB1 receptor and is inactive in vivo. A quantitative structure-activity relationship study of the side chain region of these compounds is consistent with the concept that for optimum affinity and potency the side chain must be of a length which will permit its terminus to loop back in proximity to the phenolic ring of the cannabinoid. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00649-1

文献信息

• MODIFIER FOR AROMATIC POLYESTER AND AROMATIC POLYESTER RESIN COMPOSITION COMPRISING THE SAME
  申请人：TABATA Masayoshi

  公开号：US20110224343A1

  公开（公告）日：2011-09-15

  The present invention provides a modifier for aromatic polyesters which enhances the melt fluidity of aromatic polyesters without a significant decrease in the heat resistance of the aromatic polyesters, and an aromatic polyester resin composition including the modifier for aromatic polyesters. The present invention relates to a modifier for aromatic polyesters comprising polyhydric phenol residues and residues of aromatic polycarboxylic acid, acid halide or acid anhydride thereof, and the modifier comprises a material having a structure composed of a first residue selected from the group consisting of divalent residues represented by Formula (I): —Ar—W 1 x —Ar— and by Formula (II): —Ar—, the first residues being bonded to two identical or different second residues selected from the group consisting of monovalent residues represented by Formula (III): and monovalent residues represented by Formula (IV): —O—C(O)—R 7 —.

  本发明提供了一种用于芳香族聚酯的改性剂，可以增强芳香族聚酯的熔融流动性，而不明显降低芳香族聚酯的耐热性，以及包括该改性剂的芳香族聚酯树脂组合物。本发明涉及一种用于芳香族聚酯的改性剂，包括多羟基酚残基和芳香族多羧酸、酸卤或其酸酐残基，该改性剂包括具有以下结构的材料：第一残基，选择自由式(I)所代表的二价残基：—Ar—W1x—Ar—和自由式(II)所代表的：—Ar—，第一残基与选择自由式(III)所代表的单价残基：和自由式(IV)所代表的单价残基：—O—C(O)—R7—的两个相同或不同的第二残基结合。
• CB2-selective cannabinoid derivatives
  申请人：Martin R. Billy

  公开号：US20060183922A1

  公开（公告）日：2006-08-17

  Cannabinoid derivatives that exhibit specificity for the CB 2 cannabinoid receptor are provided. The analogues are tetrahydrocannabinols and hydroxyhexahydrocannabinols, and are useful for the treatment of pain, inflammation, and cancer.

  提供了具有对CB2大麻素受体特异性的大麻素衍生物。这些类似物是四氢大麻酚和羟基六氢大麻酚，可用于治疗疼痛、炎症和癌症。
• Synthesis and pharmacology of 11-nor-1-methoxy-9-hydroxyhexahydrocannabinols and 11-nor-1-deoxy-9-hydroxyhexahydrocannabinols: New selective ligands for the cannabinoid CB2 receptor
  作者：Karla-Sue C. Marriott、John W. Huffman、Jenny L. Wiley、Billy R. Martin

  DOI：10.1016/j.bmc.2005.11.023

  日期：2006.4

  receptor. Exceptionally high CB2 affinity was observed for 1-deoxy-9beta-hydroxy-dimethylhexylhexahydrocannabinol (JWH-361, 9, n = 3) K(i) = 2.7 nM and 1-deoxy-9beta-hydroxydimethylpentylhexahydrocannabinol (JWH-300, 9, n = 2) K(i) = 5.3 nM. In general, the stereochemistry of the 9-hydroxy group is important and the beta-orientation enhances both CB2 receptor affinity and selectivity.

  通过间苯二酚前体的初始路易斯酸催化重排，合成了14种新颖的CB2受体选择性大麻素，以获得大麻素部分。它们是1-甲氧基-9-羟基六氢大麻酚和1-脱氧-9-羟基六氢大麻酚，在大麻素核的C-3处具有4至7个碳原子的1'，1'-二甲基烷基侧链。本文合成和描述的大麻酚对CB2受体的亲和力均大于对CB1受体的亲和力。观察到1-deoxy-9beta-羟基-二甲基己基六氢大麻酚具有极高的CB2亲和力（JWH-361，9，n = 3）K（i）= 2.7 nM和1-deoxy-9beta-羟基二甲基戊基六氢大麻酚（JWH-300，9，n = 2）K（i）= 5.3 nM。一般来说，
• 2-CYCLOALKYL RESORCINOL CANNABINERGIC LIGANDS
  申请人：NORTHEASTERN UNIVERSITY

  公开号：US20150274623A1

  公开（公告）日：2015-10-01

  The present invention relates to novel 2-cycloalkyl resorcinol compounds; to pharmaceutical compositions comprising the compounds; and to methods of preparing the compounds and uses thereof. The disclosed compounds can bind to and modulate the cannabinoid receptors and thus, they are specific ligands for these receptors. The invented compounds, when administered in a therapeutically effective amount to an individual or animal, results in a sufficiently high level of that compound in the individual or animal to cause a physiological response. The physiological response may be useful to treat a number of physiological conditions.

  本发明涉及一种新型的2-环烷基邻苯二酚化合物；涉及含有该化合物的药物组合物；以及制备该化合物和使用该化合物的方法。所披露的化合物能够结合和调节大麻素受体，因此它们是这些受体的特异性配体。当以治疗有效量的方式给予这些发明化合物给个体或动物时，会在个体或动物中产生足够高的该化合物水平以引起生理反应。这种生理反应可能有助于治疗许多生理状况。
• Protecting-Group-Free Synthesis of Novel Cannabinoid-Like 2,5-Dihydrobenzoxepines
  作者：Oliver Kayser、Gia-Nam Nguyen、Erin Noel Jordan

  DOI：10.1055/s-0042-1751361

  日期：2022.12

  An efficient synthesis of 2,5-dihydrobenzoxepine analogues was developed without using protecting groups. Regioselective allylation was optimized through a recent method utilizing magnesium dicarboxylates. Grubbs catalysts were applied to investigate ring-closing metathesis. The scope of the present route was extended to produce four analogues, which provided novel cannabinoid-like 2,5-dihydrobenzoxepines

  开发了一种不使用保护基团的 2,5-二氢苯并氧杂环庚烷类似物的有效合成方法。区域选择性烯丙基化通过最近使用二羧酸镁的方法进行了优化。Grubbs 催化剂用于研究闭环复分解。本路线的范围扩大到生产四种类似物，这些类似物提供了足够数量的新型大麻素样 2,5-二氢苯并氧西平，以允许对重组 CB1/CB2 受体进行体外测定。与 CB1/CB2 受体相关的体外试验未显示任何活性。